• Tonix investor presentation highlighted TONMYA’s commercial ramp, citing USD 11 million net sales in 2Q’26.
• Total net product revenue reached USD 13.5 million in 2Q’26, supported by 12,592 prescriptions and 197% growth versus Q1’26.
• Cash and cash equivalents totaled USD 176.2 million at June 30, 2026, with no debt; runway expected into early Q2’27.
• Pipeline priorities include an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention targeted for 1Q’27.
• TNX-102 SL label expansion programs include a potentially pivotal Phase 2 study in major depressive disorder; Phase 2 topline data expected mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.